Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Morgan Stanley Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
January 27, 2025 12:54 PM ESTMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $200.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "Updated results from the pivotal EMBARK study, demonstrated consistent and durable benefits in patients switched to Elevidys (Part 2, crossover) and those two years... More
